Search This Blog

Saturday, May 25, 2024

'Biden plans to address Trump ‘hush money’ verdict from the White House: report'

 President Biden plans to address former President Donald Trump’s Manhattan criminal trial in a “White House setting” when the jury delivers its verdict, according to a report. 

The 81-year-old president’s message will be tailored to the outcome of the trial, according to Politico, but in any scenario, he intends to stress that the US legal system worked and Americans should respect the process. 

Biden will deliver remarks whether the 77-year-old former president is convicted, acquitted or the jury cannot agree on a verdict. 

President Biden plans to address former President Donald Trump’s Manhattan criminal trial in a “White House setting” when the jury delivers its verdict.Pool/ABACA/Shutterstock

Closing arguments in Trump’s trial over alleged hush money payments made to porn star Stormy Daniels are set to commence on Tuesday. 

It is believed that the jury could reach a verdict as early as next week. 

The exact timing and setting of Biden’s speech have not been definitively determined, but it won’t be done on the campaign trail, multiple sources told the outlet. 

In an effort to have his remarks not perceived as being political, Biden will deliver them from the White House grounds. 

Biden will deliver remarks whether Trump is convicted, acquitted or the jury cannot agree on a verdict. AP

The Biden campaign is also prepping for the historic verdict, reportedly considering referring to the presumptive GOP nominee for president in social media posts as “Convicted Felon Donald Trump” if he’s found guilty. 

A poll released by the Cook Political Report on Thursday found that a majority of swing state voters are more worried about Biden’s age than Trump’s criminal cases.

Closing arguments in Trump’s trial over alleged hush money payments made to porn star Stormy Daniels are set to commence on Tuesday. AP

When voters in Arizona, Michigan, Pennsylvania, Nevada, North Carolina, Georgia and Wisconsin were asked whether Trump’s “temperament and legal issues” or Biden’s “age and ability to perform his duties” were more concerning, more than half (53%) responded that the president’s stage of life and mental acuity were more troubling than the former president’s four criminal cases and the two civil judgments against him. 

The Post has reached out to the White House for comment. 

https://nypost.com/2024/05/25/us-news/biden-to-address-trump-hush-money-verdict-from-wh/

Friday, May 24, 2024

US Weapons Accuracy Drops to 10 Percent in Ukraine Due to Jamming

 Many high-tech US weapons systems in Ukraine are now useless due to jamming signals by Russia.

Useless Weapons

Please consider Russian Jamming Leaves Some High-Tech U.S. Weapons Ineffective in Ukraine

Russia’s jamming of the guidance systems of modern Western weapons, including Excalibur GPS-guided artillery shells and the High Mobility Artillery Rocket System, or HIMARS, which can fire some U.S.-made rockets with a range of up to 50 miles, has eroded Ukraine’s ability to defend its territory and has left officials in Kyiv urgently seeking help from the Pentagon to obtain upgrades from arms manufacturers.

The success rate for the U.S.-designed Excalibur shells, for example, fell sharply over a period of months — to less than 10 percent hitting their targets — before Ukraine’s military abandoned them last year, according to the confidential Ukrainian assessments.

Six months ago, after Ukrainians reported the problem, Washington simply stopped providing Excalibur shells because of the high failure rate, the Ukrainian officials said, speaking on the condition of anonymity to discuss a sensitive security matter. In other cases, such as aircraft-dropped bombs called JDAMs, the manufacturer provided a patch and Ukraine continues to use them.

Russia’s invasion of Ukraine created a modern testing ground for Western arms that had never been used against a foe with Moscow’s ability to jam GPS navigation.

But even before the United States ceased deliveries, Ukrainian artillerymen had largely stopped using Excalibur, the assessments said, because the shells are harder to use compared with standard howitzer rounds, requiring time-consuming special calculations and programming. Now they are shunned altogether, military personnel in the field said.

Dense web of jamming
A web of Russian electronic warfare systems and air defenses menace Ukrainian pilots, the documents said, adding that some Russian jammers also scramble the navigation system of planes. The Russian defense is so dense, the assessment found, that there are “no open windows for the Ukrainian pilots where they feel that they are not at gunpoint.”

HIMARS launchers were celebrated during the first year of Russia’s invasion for their success in striking ammunition depots and command points behind enemy lines.

But by the second year, “everything ended: the Russians deployed electronic warfare, disabled satellite signals, and HIMARS became completely ineffective,” a second senior Ukrainian military official said. “This ineffectiveness led to the point where a very expensive shell was used” increasingly to strike lower-priority targets.

Another US Precision-Guided weapon Fails

Defense One reports Another US Precision-Guided Weapon Falls Prey to Russian Electronic Warfare

A new ground-launched version of an air-to-ground weapon developed for Ukraine on a rapid timeline failed to hit targets in part because of Russian electro-magnetic warfare, Bill LaPlante, the Pentagon’s acquisition chief, said at an event held by think tank CSIS.

LaPlante suggested that Ukraine may no longer be interested in the weapon. “When you send something to people in the fight of their lives that just doesn’t work, they’ll try it three times and they’ll just throw it aside,” said LaPlante.

The weapon LaPlante is referring to is very likely the Ground-Launched Small Diameter Bomb (GLSDB) based on his description, according to Bryan Clark, a senior fellow at the Hudson Institute.

A Boeing spokesperson did not confirm that LaPlante was referring to GLSDB, but said the company is “working closely with the [Defense Department] on spiral capability improvements to the ground-launch SDB system.” Spiral capability improvements refers to an iterative software development process.

The GLDSB boasts a range of 90 miles—double the range of the Guided Multiple Launch Rocket System (GMRLS) missiles Ukraine previously used to wreak havoc on Russia’s logistic centers. Funding for the weapon was approved in February 2023, and Ukraine was reportedly using the weapon by February 2024.

GPS spoofers work by sending false location data to GPS navigation devices. Because GPS signals are weak, a stronger, false signal can be sent to override the correct inputs. Russia has used GPS spoofing in Ukraine since at least 2018. But advancements in technology mean spoofers can be created cheaply with just a software-defined radio and open-source software.

The weapons the spoofers are working against, meanwhile, are anything but cheap. A GMLRS missile costs around $160,000, while an Excalibur round can cost as much as $100,000. The GLDSB costs around $40,000.

Tactical Nuclear Weapons

Former CIA analyst Larry Johnson on Sullivan’s words about Russia’s plans to use nuclear weapons: “His statement sounds like he had a meeting with Zelensky, where he was given some of Zelensky’s cocaine. Russia will not use nuclear weapons unless there is a real threat. If the US deploys F-16s in Poland, then Russia will destroy them “with conventional weapons, because they do pose a nuclear threat. The Taurus missiles are the same situation. If they are deployed, then you know – Russia has admitted that they can be used to launch a nuclear strike.”

Use Nukes First

Would You Mind Not Shooting at the Thermonuclear Weapons?

Get Russia to Strike First

Using Nukes First Is a Risk/Reward Setup

Is Nuclear War Bullish?

What’s the Real Background Story Behind Russia’s Invasion of Ukraine?

On February 24, 2022 I asked, and answered the question What’s the Real Background Story Behind Russia’s Invasion of Ukraine?

What Happened in Ukraine?

The mess today in Ukraine has its roots in the 2014 when democratically elected Ukrainian President Yanukovych was toppled in a US-backed coup. 

Q: Why did the US want to get rid of Yanukovych? 

A: Because he was against Ukraine joining NATO.

The current comedian president of Ukraine, Volodymyr Zelenskyy, repeated two days ago his desire to join NATO.

I use the term comedian because he literally is a comedian who ran for office and won.

McCain dined with Svoboda Party leader Oleg Tyagnibok. The Svoboda Party is a group of neo-Nazis. 

The citizens of Ukraine were used as pawns in yet another US mission that backfired. 

Well who cares about Neo-Nazis as long as they want Ukraine in NATO.

And that’s the rest of the story US media will not discuss. 

This no way absolves Putin, but US meddling backfires again, and again, and again.

Sometimes the Best Thing to Do Is Nothing At All

Please consider Sometimes the Best Thing to Do Is Nothing At All

After pointing out how much US and EU sanctions have backfired, someone asked me what I would do.

I responded, why do I have to do anything? 

The urge to do something should not be so intense that it overpowers analysis as to whether any actions can possibly work.

President Biden on Putin

On March 26, President Biden proclaimed “For God’s Sake, this Man Cannot Remain in Power”

The Wall Street Journal and perpetual warmongers agreed. But Biden’s staff quickly backtracked on his controversial statement.

On March 29 I pointed out all the loopholes in  sanctions on Russia, For discussion, please see Misguided Souls Still Do Not Understand This Simple Truth: Sanctions Don’t Work

I wrote that on April 8, 2022.

Also in 2022, I said the war would end in a negotiated settlement and nobody would win.

What did I get wrong?

It’s Time for a New Strategy

On March 16, I wrote Ukraine Won’t Win the War, It’s Time for a New Strategy

The sad thing is US meddling precipitated this whole sorry affair.

It’s time for a new strategy and a goal: Negotiated settlement.

If we supply Ukraine with anything, we should only do so if it aids that goal. For now, we still have no goals.

What’s the Goal?

On November 7, 2023, I asked If the US Has a Goal in Ukraine or Israel, What the Hell Is It?

We still don’t have a clearly defined goal or a clearly defined amount of money we are willing to spend.

Any Questions?

I have one:

Given US meddling in Ukraine precipitated this war, are we obliged to start a nuclear war to stop it, or is the lesson to just stop meddling?

https://mishtalk.com/economics/us-weapons-accuracy-drops-to-10-percent-in-ukraine-due-to-jamming/

First McDonald's, Now Burger King Admits Consumers Are Broke With Planned Reintro Of $5 Meal

 A recent trend of mega corporations rolling back prices and reintroducing deals has emerged. Whether this is potentially due to pressure from the White House ahead of elections or, as Goldman pointed out, "Consumer caution mounts as cracks in resilience theme emerge," there's growing evidence that working poor consumers are struggling in the era of failed Bidenomics.

About two weeks ago, after three years of 'McFlation' that sent the price of combo meals as high as $18, McDonald's weighed on new plans to reintroduce $5 combo meal deals. The report, initially from Bloomberg, specified the deal could include a McChicken or a McDouble, fries, and a drink. 

Elsewhere, Walmart, Target, and Aldi have lowered prices on thousands of everyday items, including staple foods. This comes in response to a spending slowdown among cash-strapped working-poor consumers who are drowning in insurmountable credit card debt and drained personal savings amid elevated inflation. 

Covering the faltering consumer theme have been the analysts at Goldman: 

The value war kicked off earlier this month as corporations strive to retain their customer base and prevent trade-downs or migrations to competitors. This is why McDonald's meal deal push has prompted Burger King to offer a similar deal. 

Bloomberg reported that Burger King is preparing to launch a $5 meal deal. The deal will include the choice of one of three sandwiches with nuggets, fries, and a drink. Franchisees approved the deal in April. 

"Regardless of their plans, we are moving full speed ahead with our own plans to launch our own $5 value meal before they do — and run it for several months," Burger King US and Canada President Tom Curtis wrote in an internal memo obtained by Bloomberg. 

The bigger story is that mega-corporations are cutting prices and offering deals because, as Goldman has shown, working-poor consumers have hit a proverbial brick wall. 

https://www.zerohedge.com/markets/first-mcdonalds-now-burger-king-admits-are-broke-planned-reintroduction-5-meal

Vanda Board: Unsolicited Takeover Proposal Not in Best Interests

 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board") carefully reviewed the revised unsolicited proposal from Future Pak, LLC ("FP") to acquire the Company for $7.25 to $7.75 per share in cash plus certain Contingent Value Rights ("CVRs") and, after having consulted with the Company's independent financial and legal advisors, unanimously concluded that the proposal substantially undervalues the Company, creates significant risk and uncertainty and is not in the best interests of the Company and its shareholders. Accordingly, the Board has rejected the proposal.

In reaching its conclusion, the Board evaluated all aspects of Vanda's business, including its clinical development pipeline, expanding commercial presence and significant cash balance, as well as the speculative nature of the CVRs given the uncertainty surrounding the achievement of the commercial milestones under FP's management. The Board believes the revised unsolicited proposal is yet another opportunistic attempt to purchase the Company's shares at a discount to Vanda's intrinsic value.

The Board and management team remain confident that Vanda's robust revenue, strong cash position and efficient operations position the Company well for significant long-term growth and value creation far in excess of the consideration offered by FP.

There is no action for shareholders to take at this time.

https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-board-of-directors-determines-that-revised-unsolicited-takeover-proposal-is-not-in-the-best-interests-of-the-company-and-its-shareholders-302155506.html

House GOP Aim At Biden Energy Policies, Vow To Install "Different Vision" In 2025

 by John Haughey via The Epoch Times,

The Republican-led House Oversight and Accountability Committee staged its 15th review in the last 15 months of the Biden administration’s energy policies during a two-hour May 23 hearing that Democrats say was orchestrated more as a forum for election-year rhetoric than for a sober assessment of energy policy and Department of Energy (DOE) spending proposals.

DOE Secretary Jennifer Granholm was grilled over administration plans to domestically source critical minerals, adopt conservation standards for appliances, advance commercial nuclear power, restore the Strategic Petroleum Reserve, boost electric grid reliability, provide billions in subsidies for renewable energies, its liquid natural gas (LNG) export-permit “pause,” and even how it deals with UFO sightings around power plants.

Much of Ms. Granholm’s give-and-take with panelists was more semantics than substance, such as lengthy exchanges with Reps. Clay Higgins (R-La.), Scott Perry (R-Pa.), and Byron Donalds (R-Fla.) on whether the administration’s January “pause” in new LNG export permits is, in effect, a “ban.”

Under the Natural Gas Act’s (NGA) Section 3, the DOE is required to review applications for import or export of natural gas, including LNG, to or from a foreign country and approve those deemed “consistent with the public interest.”

Advances in fracking spurred a natural gas boom. Before 2016, the U.S. did not export LNG. By 2023, it was the world’s top LNG exporter. This year, LNG exports will top 12 billion cubic feet per day (Bcfd) and are expected to increase to 14 Bcfd in 2025—all records, Ms. Granholm said, noting repeatedly that the “pause” does not affect operating and already approved LNG exports.

“By the time all authorized projects currently under construction are complete later this decade, our export capacity is set to reach over 26 Bcfd, more than double our current level of exports,” she said. “The United States will have more LNG export capacity than any other country by more than 40 percent, even taking into account announced capacity additions in other countries.”

Mr. Higgins and other panel Republicans said the DOE overstepped its statutory authority in unilaterally ordering a permitting pause to determine if increasing LNG exports serves “the public interest” in ensuring ample domestic supply keeps prices competitive and maintains the administration’s overriding goals in reducing carbon emissions.

“Why have you issued a long-term ban on export permit approvals prior to determining whether or not exporting LNG is within the public interest?” he asked.

“Number one, we have not issued a ban. Number two, it is not long-term. It is a pause to update our assessment,” Ms. Granholm said. “The assessment will be done by the first quarter of next year. It is not a ban, sir.”

“It is a ban,” Mr. Higgins said, claiming he was “not going to get a straight answer” from the secretary, “which is not a bad answer,” and read into the record the NGA’s Section 3, which states DOE “shall issue such an order upon application unless, after opportunity for a hearing … that the proposed exportation or importation will not be consistent with the public interest.”

There was no such hearing or determination, he said, so the NGA’s language states, by default, that export permits “shall be” issued unless deemed not in the public interest in a hearing. The Obama administration conducted a similar 2014-15 assessment without pausing permits, he added.

“You do not have the authority, nor the precedence, to take the actions that you have, indeed, taken,” Mr. Higgins said. “This pause jeopardizes billions of dollars of interest, American jobs, American families, and a clean reliable energy source that contributes to our national security and energy security and world security by allies. This is yet another illegal action by the Biden administration being forced upon we the people.”

Ms. Granholm said under NGA’s Section 3, the sharp increase in LNG exports provides the statutory authority to conduct a “public interest” review, repeating again it will be done by February 2025 and does not affect any permits already approved.

“You have put in a pause and you saying it’s in the ‘public interest,’” Mr. Donalds said. “But you can’t really identify what the ‘public interest’ is because it’s in the ‘public’s interest’ for prices to go down. It is in America’s ‘public interest’ to limit the ability of the Russian regime to earn more money on the open market with their resources. Wouldn’t you agree with that?”

No, Ms. Granholm said. Determining “public interest” is what the review is about, she said.

“I would argue, madam secretary, that the pause that you are doing is against the law because you have not finalized your parameters, what you’re looking at” in defining “public interest,” Mr. Donalds said. “You do need to execute the permits that are waiting.”

A model of an LNG tanker is seen in front of the U.S. flag in this illustration taken May 19, 2022. (Dado Ruvic/Reuters)

Rep. Jamie Raskin (D-Md.) said Republicans were asking the same questions they’ve asked for months, with this hearing more about campaign sound bites than a substantive discussion on energy policy.

What impact will the pause have on current LNG exports into “the foreseeable future?” Mr. Raskin asked, hoping to “restore some sense of proportion and reality to the conversation.”

“It has absolutely no impact on any exports happening now,” Ms. Granholm said. “We have authorized 48 billion cubic feet of export of liquefied natural gas—48 billion. That is three times what we are currently exporting. We have authorized another 22 billion (cubic feet)” for export from terminals and projects under construction.”

The “oversight” hearings aren’t about accountability, efficiency, and cost-savings, Mr. Raskin said, but to provide forums for Republicans to tout opposition to the Biden administration’s “war on energy’” and make “convoluted rhetorical claims” that make for good campaign sound bites, but not for thoughtful discussion.

But elections have consequences, and winning the House in the 2022 midterms put GOP chairs in committees, and they will tort their opposition to the Biden administration’s “green energy obsession” as often as they can.

Committee chair Rep. James Comer (R-Ky.) said Republicans, not Democrats, are seeking substantive answers to energy policy questions that have dominated Congress since President Joe Biden assumed office in January 2021.

Expect more such hearings into fall, he said.

“While Democrats politicize energy and target American producers,” gasoline prices and electricity costs have increased by 30 percent since 2021, he said.

“Congressional Republicans share a different vision for America’s energy future,” Mr. Comer said. “We will not stand by silently about as an administration subverts America’s energy independence and demonizes this critical industry.”

https://www.zerohedge.com/political/house-republicans-take-aim-biden-energy-policies-vow-install-different-vision-2025

ASCO24: Regeneron’s Bispecific Antibody Falls Flat in Early Study

 Regeneron Pharmaceuticals on Thursday released early data from the ongoing Phase I/II study of its investigational bispecific antibody REGN7075, demonstrating underwhelming treatment response results in patients with advanced solid tumors.

As of the data cut-off in October 13, 2023, only one patient out of 94 achieved complete response while two showed partial response, according to an abstract published ahead of the American Society of Clinical Oncology annual meeting next week. One additional patient, who had liver metastasis, reached partial response after the cut-off. Nine patients had stable disease.

The resulting overall response rate was 20% while the disease control rate was 80%. Israel Lowy, senior vice president of translational and clinical oncology at Regeneron, in a statement struck an optimistic tote noting that the findings “speak to the potential” of REGN7075 as a treatment for solid tumors.

The early data also “add to a growing body of evidence supporting novel costimulatory bispecifics that are in clinical trials for a range of solid tumors and blood cancers,” Lowy added.

REGN7075 is a first-in-class costimulatory bispecific antibody that works by bridging CD28-positive T cells with tumor cells expressing the EGFR protein. This mechanism of action allows REGN7075 to restore the immune sensitivity of tumor cells and activate the anti-cancer functions of T-cells.

Regeneron’s Phase I/II study is a first-in-human open-label trial testing the investigational antibody, in combination with the company’s PD-1 blocker Libtayo (cemiplimab-rwlc), as a treatment for patients with metastatic and locally advanced solid tumors who have exhausted standard treatment options.

The study has two parts: a Phase I dose-escalation portion, which includes a lead-in period with REGN7075 monotherapy, and a Phase II dose-expansion portion. Beyond efficacy, the primary goal of the early-stage study is to assess the safety and tolerability of the REGN7075 regimen. The candidate’s overall profile was “acceptable,” according to Regeneron.

Almost all patients developed treatment-emergent adverse events (TEAE), though only 35% of participants saw grade 3 or 4 TEAEs. Toxicities deemed related to the study drug arose in 90% of patients, but only 7% of these side effects were grade 3 or 4. In addition, 5% of patients dropped out of the study due to side effects. There have been no treatment-related deaths so far.

Thursday’s readout continues Regeneron’s rough patch in cancer. In March 2024, the pharma failed to secure the FDA’s approval for another bispecific antibody, odronextamab, for the treatment of relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma. The rejection came despite promising Phase II data for the candidate published in December 2023.

Another Regeneron bispecific, linvoseltamab, returned mixed data in December 2023. In patients with relapsed or refractory multiple myeloma, the candidate elicited a 71% objective response rate but showed high rates of adverse events, with 85% of treated patients experiencing side effects at least grade 3 in severity.

https://www.biospace.com/article/asco24-regeneron-s-bispecific-antibody-falls-flat-in-early-study-with-just-one-complete-response/

ASCO24: J&J Reports Four Patient Deaths in Early-Stage Prostate Cancer Trial

 Four patients died in Johnson & Johnson’s Phase I study for its investigational targeted radiopharmaceutical candidate JNJ-6420 in metastatic castration-resistant prostate cancer, according to a Thursday readout released ahead of next week’s American Society of Clinical Oncology annual meeting.

Thursday’s data come from 57 patients who had received at least one dose of JNJ-6420, of whom 31 stayed on treatment for 24 weeks or longer. At the time of the interim analysis, three patients had confirmed objective response, including one patient who showed complete response.

Almost half of the patients who had received at least a 150-μCi dose of the candidate saw a 50% decline in prostate-specific antigen levels, while 14% reached this benchmark. At six months, disease control rate was 28.1%.

According to the abstract, the results suggest that one to two doses of 150-μCi JNJ-6420 can elicit “profound and durable biochemical and radiographic responses” in treated patients.

However, in terms of safety, J&J’s investigational radiotherapy appears to be fairly toxic. More than 60% of patients developed treatment-emergent adverse events (TEAE) that were at least grade 3 in severity, while almost 37% had a serious TEAE. Common adverse events included anemia, low platelet count and abnormal reductions in white blood cells.

Nine patients dropped out of the study due to severe side effects that were deemed related to the study drug.

JNJ-6420 is a potentially first-in-class targeted radiopharmaceutical candidate that works by using an anti-hK2 antibody to deliver an actinium-based radioligand. The payload can emit high-energy alpha particles across short ranges, allowing JNJ-6420 to specifically target prostate cancer cells.

With Thursday’s readout, J&J joins the growing number of companies that have started pumping dollars in the emerging targeted radiopharma field. Among them is Bristol Myers Squibb’s acquisition of RayzeBio for $3.6 billion in December 2023. Like JNJ-6420, RayzeBio’s candidates use actinium-based payloads. Its lead program, RYZ101, is being developed for gastroenteropancreatic neuroendocrine tumors and small-cell lung cancer.

In March 2024, AstraZeneca also joined the radiopharma race with its potential $2.4 billion acquisition of Fusion Pharmaceuticals, which is also working on an actinium-based candidate. Its lead program is FPI-2265, which will face off against JNJ-6420 in metastatic castration-resistant prostate cancer.

Earlier this month, Novartis also bet $1 billion in radiopharma by buying Mariana Oncology and was followed by Eli Lilly, which on Tuesday entered a $1.1 billion partnership with Aktis Oncology.

https://www.biospace.com/article/asco24-j-and-j-reports-four-patient-deaths-in-early-stage-radiotherapy-prostate-cancer-trial/